3
Orphan Designations
0 approved, 3 designated
1
FDA Approvals
Latest: ILLUCCIX (2021)
0
Active Trials
2
Rare Diseases
across 4 areas
0
News (30d)
Quiet
Telix Pharmaceuticals (US) Inc. is a company with 3 orphan drug designations across 2 rare diseases, including 1 FDA-approved therapy.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| glioma | 4-[131I]iodo-L-phenylalanine | Des.TrialAppr. |
| malignant glioma | 4-[211At]astato-L-phenylalanine | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio